Co-Diagnostics, Inc. (CODX) has regained compliance with Nasdaq listing requirements, including the $1.00 minimum bid price rule, and its shares have resumed trading on Nasdaq as of March 11, 2026.
Co-Diagnostics develops molecular diagnostic technologies, including its proprietary Co-Dx PCR platform for point-of-care and at-home testing, which remains under regulatory review.
The company emphasized that regaining compliance strengthens its ability to pursue clinical performance studies and regulatory clearance pathways.
The company implemented a 1-for 30 reverse stock split on December 29, 2025.
CODX is currently trading at $4.40, up 101.83%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.